Small-Molecule Inhibitors Specifically Targeting Type III Secretion

ABSTRACT The type III secretion (TTS) system is used by several animal and plant pathogens to deliver effector proteins into the cytosol of the eukaryotic target cell as a strategy to evade the defense reactions elicited by the infected organism. The fact that these systems are highly homologous implies that novel antibacterial agents that chemically attenuate the pathogens via a specific interaction with the type III secretion mechanism can be identified. A number of small organic molecules having this potential have recently been identified (A. M. Kauppi, R. Nordfelth, H. Uvell, H. Wolf-Watz, and M. Elofsson, Chem. Biol. 10:241-249, 2003). Using different reporter gene constructs, we showed that compounds that belong to a class of acylated hydrazones of different salicylaldehydes target the TTS system of Yersinia pseudotuberculosis. One of these compounds, compound 1, was studied in detail and was found to specifically block Yop effector secretion under in vitro conditions by targeting the TTS system. In this respect the drug mimics the well-known effect of calcium on Yop secretion. In addition, compound 1 inhibits Yop effector translocation after infection of HeLa cells without affecting the eukaryotic cells or the bacteria. A HeLa cell model that mimics in vivo conditions showed that compound 1 chemically attenuates the pathogen to the advantage of the eukaryotic cell. Thus, our results show proof of concept, i.e., that small compounds targeting the TTS system can be identified, and they point to the possible use of TTS inhibitors as a novel class of antibacterial agents.

[1]  K. Poole.  Multidrug resistance in Gram-negative bacteria. , 2001, Current opinion in microbiology.

[2]  Roger G. Linington,et al.  Caminoside A, an antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia. , 2002, Organic letters.

[3]  T. Bergman,et al.  Modulation of Virulence Factor Expression by Pathogen Target Cell Contact , 1996, Science.

[4]  T. Mitchison,et al.  A small-molecule approach to studying invasive mechanisms of Toxoplasma gondii. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Hueck,et al.  Type III Protein Secretion Systems in Bacterial Pathogens of Animals and Plants , 1998, Microbiology and Molecular Biology Reviews.

[6]  K. Ramamurthi,et al.  YopD and LcrH Regulate Expression of Yersinia enterocolitica YopQ by a Posttranscriptional Mechanism and Bind to yopQ RNA , 2002, Journal of bacteriology.

[7]  H. Wolf‐Watz,et al.  Inhibition of phagocytosis in Yersinia pseudotuberculosis: a virulence plasmid-encoded ability involving the Yop2b protein , 1988, Infection and immunity.

[8]  G. Cornelis,et al.  Assembly and function of type III secretory systems. , 2000, Annual review of microbiology.

[9]  H. Wolf‐Watz,et al.  A novel protein, LcrQ, involved in the low-calcium response of Yersinia pseudotuberculosis shows extensive homology to YopH , 1992, Journal of bacteriology.

[10]  G. Cornelis,et al.  The Type III secretion system of Gram-negative bacteria: a potential therapeutic target? , 2001, Expert opinion on therapeutic targets.

[11]  A. Plückthun,et al.  An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments. , 1994, BioTechniques.

[12]  B. Wren.  The Yersiniae — a model genus to study the rapid evolution of bacterial pathogens , 2003, Nature Reviews Microbiology.

[13]  A Bairoch,et al.  Arac/XylS family of transcriptional regulators , 1997, Microbiology and molecular biology reviews : MMBR.

[14]  C. Ginocchio,et al.  Functional conservation among members of the Salmonella typhimurium InvA family of proteins , 1995, Infection and immunity.

[15]  K. Magnusson,et al.  YopK of Yersinia pseudotuberculosis controls translocation of Yop effectors across the eukaryotic cell membrane , 1997, Molecular microbiology.

[16]  D. Dauzonne,et al.  SYNTHESIS OF THE 3-AMINOFLAVONE-8-ACETIC ACID , 1995 .

[17]  G. Cornelis,et al.  Mutational analysis of the Yersinia enterocolitica virC operon: characterization of yscE, F, G, I, J, K required for Yop secretion and yscH encoding YopR , 1995, Molecular microbiology.

[18]  J. Goguen,et al.  Temperature-controlled plasmid regulon associated with low calcium response in Yersinia pestis , 1986, Journal of bacteriology.

[19]  T. Nagasu,et al.  Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly , 2003, Molecular microbiology.

[20]  A. Holmström,et al.  Cell‐surface‐bound Yersinia translocate the protein tyrosine phosphatase YopH by a polarized mechanism into the target cell , 1995, Molecular microbiology.

[21]  I. Rundquist,et al.  Use of cytofluorometry to evaluate binding of antibodies to the cytoskeleton of cultured cells. , 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[22]  H. Wolf‐Watz,et al.  YopB of Yersinia enterocolitica Is Essential for YopE Translocation , 2001, Infection and Immunity.

[23]  Philip K. Russell,et al.  Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 2000, JAMA.

[24]  G. Cornelis,et al.  The Yersinia Yop virulon: a bacterial system for subverting eukaryotic cells , 1997, Molecular microbiology.

[25]  S. Chanteau,et al.  Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. , 1997, The New England journal of medicine.

[26]  H. Wolf‐Watz,et al.  The virulence protein Yop5 of Yersinia pseudotuberculosis is regulated at transcriptional level by plasmid‐plB1 ‐encoded trans‐acting elements controlled by temperature and calcium , 1988, Molecular microbiology.

[27]  T. Bergman,et al.  The cytotoxic protein YopE of Yersinia obstructs the primary host defence , 1990, Molecular microbiology.

[28]  H. Wolf‐Watz,et al.  Virulence plasmid-associated HeLa cell induced cytotoxicity of Yersinia pseudotuberculosis. , 1986, Microbial pathogenesis.

[29]  S. Projan,et al.  Bacterial virulence as a target for antimicrobial chemotherapy. , 2000, Current opinion in biotechnology.

[30]  B. Finlay,et al.  Pachymoside A: A novel glycolipid isolated from the marine sponge Pachymatisma johnstonia , 2004 .

[31]  Nicholas J Westwood,et al.  Using small molecules to study big questions in cellular microbiology , 2002, Cellular microbiology.

[32]  W. Denny,et al.  Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure-activity relationships. , 1999, Journal of inorganic biochemistry.

[33]  H. Wolf‐Watz,et al.  Salicylanilides are potent inhibitors of type III secretion in Yersinia. , 2003, Advances in experimental medicine and biology.

[34]  C. Walsh.  Opinion — anti-infectives: Where will new antibiotics come from? , 2003, Nature Reviews Microbiology.

[35]  G. Cornelis,et al.  Homology between virF, the transcriptional activator of the Yersinia virulence regulon, and AraC, the Escherichia coli arabinose operon regulator , 1989, Journal of bacteriology.

[36]  K. Magnusson,et al.  Target cell contact triggers expression and polarized transfer of Yersinia YopE cytotoxin into mammalian cells. , 1994, The EMBO journal.

[37]  E. Hamilton,et al.  Three binding sites for AraC protein are required for autoregulation of araC in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Cornelis,et al.  Transcription of the yop regulon from Y. enterocolitica requires trans acting pYV and chromosomal genes. , 1987, Microbial pathogenesis.

[39]  S. Hultgren,et al.  Targeting virulence for antimicrobial chemotherapy. , 2003, Current opinion in pharmacology.

[40]  R. Rosqvist,et al.  In vivo expression of virulence genes of Yersinia pseudotuberculosis. , 1993, Infectious agents and disease.

[41]  D. Livermore.  Can better prescribing turn the tide of resistance? , 2004, Nature Reviews Microbiology.

[42]  Yanping Wang,et al.  Human intestinal bacteria as reservoirs for antibiotic resistance genes. , 2004, Trends in microbiology.

[43]  H. Blöcker,et al.  Molecular cloning of the plasmid RP4 primase region in a multi-host-range tacP expression vector. , 1986, Gene.

[44]  G. Cornelis.  The Yersinia Ysc–Yop 'Type III' weaponry , 2002, Nature Reviews Molecular Cell Biology.

[45]  G. Cornelis,et al.  Insertion of a Yop translocation pore into the macrophage plasma membrane by Yersinia enterocolitica: requirement for translocators YopB and YopD, but not LcrG , 1999, Molecular microbiology.

[46]  H. Wolf‐Watz,et al.  The YopB protein of Yersinia pseudotuberculosis is essential for the translocation of Yop effector proteins across the target cell plasma membrane and displays a contact‐dependent membrane disrupting activity. , 1996, The EMBO journal.

[47]  Hans Wolf-Watz,et al.  Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. , 2003, Chemistry & biology.

[48]  M. Skurnik,et al.  The surface‐located YopN protein is involved in calcium signal transduction in Yersinia pseudotuberculosis , 1991, Molecular microbiology.

[49]  P. Cherepanov,et al.  Bmc Microbiology the Yersinia Yope and Yoph Type Iii Effector Proteins Enhance Bacterial Proliferation following Contact with Eukaryotic Cells , 2022 .

[50]  Philip K. Russell,et al.  Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.

[51]  H. Wolf‐Watz,et al.  Functional conservation of the secretion and translocation machinery for virulence proteins of yersiniae, salmonellae and shigellae. , 1995, The EMBO journal.

[52]  T. Liljefors,et al.  Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. , 1998, Journal of medicinal chemistry.

[53]  S. Straley,et al.  LcrG, a secreted protein involved in negative regulation of the low-calcium response in Yersinia pestis , 1993, Journal of bacteriology.